• Rooman, Ilse (Administrative Promotor)
  • Laethem, Van, Jean-Luc (Co-Promotor)


Pancreatic ductal adenocarcinoma (PDAC) remains one of the most
aggressive and lethal cancers. Inter-patient heterogeneity is a key problem
that has led to many failures of clinical trials, underscoring the need for a
more stratified therapeutic approach,based on PDAC taxonomy elaborated by
both applicants in separate consortia.However, pragmatic approaches to
subtyping for clinical implementation are lacking. Incorporating breakthrough
technologies, there is an opportunity to capture the position of subtypespecific
RNA expression (RNA scope) and point-mutations in situ(Base
scope) at single cell level within the morphological and spatial context of the
intact tumor tissue and after specific therapy.
1. develop a routine PDAC taxonomy using a pragmatic classifier
(the fingerprint)
2. study subtype-specific gene alterations positioning within
different tumor (epithelial) zones comprising the
microenvironment of stromal and immune components
3. study evolutional changes in the above upon neoadjuvant
therapy in a prospective cohort using a window setting clinical
trial protocol
Short titleGPS
Effective start/end date1/01/1931/12/22

    Flemish discipline codes

  • Clinical genetics and molecular diagnostics
  • Cancer biology

ID: 45331589